[go: up one dir, main page]

EE200300055A - Hüdrogeeli poolt juhitav ravimi annustamisvorm - Google Patents

Hüdrogeeli poolt juhitav ravimi annustamisvorm

Info

Publication number
EE200300055A
EE200300055A EEP200300055A EEP200300055A EE200300055A EE 200300055 A EE200300055 A EE 200300055A EE P200300055 A EEP200300055 A EE P200300055A EE P200300055 A EEP200300055 A EE P200300055A EE 200300055 A EE200300055 A EE 200300055A
Authority
EE
Estonia
Prior art keywords
dosage form
controlled drug
drug dosage
hydrogel controlled
hydrogel
Prior art date
Application number
EEP200300055A
Other languages
English (en)
Inventor
Elizabeth Appel Leah
Christian Babcock Walter
Arthur Beyerinck Ronald
Brian Chidlaw Mark
John Curatolo William
Thomas Friesen Dwayne
Max Herbig Scott
Govind Thombre Avinash
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300055A publication Critical patent/EE200300055A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300055A 2000-08-09 2001-08-03 Hüdrogeeli poolt juhitav ravimi annustamisvorm EE200300055A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22419900P 2000-08-09 2000-08-09
PCT/IB2001/001390 WO2002011702A2 (en) 2000-08-09 2001-08-03 Hydrogel-driven drug dosage form

Publications (1)

Publication Number Publication Date
EE200300055A true EE200300055A (et) 2004-12-15

Family

ID=22839665

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300055A EE200300055A (et) 2000-08-09 2001-08-03 Hüdrogeeli poolt juhitav ravimi annustamisvorm

Country Status (30)

Country Link
US (2) US20030086972A1 (et)
EP (1) EP1326587A2 (et)
JP (1) JP2004505907A (et)
KR (1) KR20030024844A (et)
CN (1) CN1461212A (et)
AP (1) AP2001002237A0 (et)
AU (1) AU2002229141A1 (et)
BG (1) BG107538A (et)
BR (1) BR0113067A (et)
CA (1) CA2418907A1 (et)
DO (1) DOP2001000229A (et)
EA (1) EA200300081A1 (et)
EC (1) ECSP034455A (et)
EE (1) EE200300055A (et)
GT (1) GT200100161A (et)
HR (1) HRP20030082A2 (et)
HU (1) HUP0300722A2 (et)
IL (1) IL154012A0 (et)
IS (1) IS6686A (et)
MA (1) MA26939A1 (et)
MX (1) MXPA03001209A (et)
NO (1) NO20030627L (et)
OA (1) OA12365A (et)
PA (1) PA8524901A1 (et)
PE (1) PE20020307A1 (et)
PL (1) PL360658A1 (et)
SV (1) SV2002000586A (et)
TN (1) TNSN01123A1 (et)
UY (1) UY26876A1 (et)
WO (1) WO2002011702A2 (et)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210078244A1 (en) * 2018-01-09 2021-03-18 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
EA004370B1 (ru) * 1999-12-23 2004-04-29 Пфайзер Продактс Инк. Лекарственная форма с высвобождением лекарства под действием гидрогеля
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
MXPA03006217A (es) 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
CN100408029C (zh) 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CA2499977A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Edible solid composition and dosage form
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
WO2004108067A2 (en) * 2003-04-03 2004-12-16 Sun Pharmaceutical Industries Limited Programmed drug delivery system
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AR040157A1 (es) * 2003-06-06 2005-03-16 Rodriguez Julio Cesar Una formulacion en microgranulos para administracion oral en suspension acuosa
BRPI0413363A (pt) * 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CA2601762A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US20060193911A1 (en) * 2005-02-28 2006-08-31 Penwest Pharmaceuticals Co., Controlled release venlafaxine formulations
CN101146521A (zh) * 2005-03-14 2008-03-19 太阳医药高级研究有限公司 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
WO2006099618A1 (en) * 2005-03-16 2006-09-21 Dr. Reddy's Laboratories Ltd. Delivery system for multiple drugs
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
CN100448433C (zh) * 2005-09-21 2009-01-07 广州贝氏药业有限公司 一种克拉霉素肠溶药物组合物
US20070248630A1 (en) * 2006-04-20 2007-10-25 Friden Phillip M Pharmaceutical formulations for iontophoretic methotrexate delivery
SA07280459B1 (ar) * 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
CA2715584A1 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd. Oral controlled release tablet
AU2010316741A1 (en) * 2009-11-09 2012-05-24 Capsugel Belgium Nv Delivery carrier
CA2793525C (en) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
CA2844604C (en) 2011-08-10 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ethanediamide derivatives
KR101644837B1 (ko) * 2013-01-30 2016-08-03 주식회사 대웅 위장관 내 상처 보호, 출혈 방지, 또는 유착 방지용 약학 조성물
MA41868A (fr) * 2015-04-01 2018-02-06 Spectrum Brands Inc Pastille retard et procédés s'y rapportant
WO2019173526A1 (en) * 2018-03-07 2019-09-12 Andrew Xian Chen Aqueous formulations for insoluble drugs
TW202313006A (zh) * 2021-05-28 2023-04-01 美商安進公司 阿普斯特配製物
CN113600179B (zh) * 2021-09-16 2023-07-04 山东博霖环保科技发展有限公司 一种脱硝催化剂及其制备方法
JPWO2023063381A1 (et) * 2021-10-14 2023-04-20

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1025765B (it) * 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
JPH05178763A (ja) * 1991-02-19 1993-07-20 Nippon Saafuakutanto Kogyo Kk 難溶解性薬物溶解剤組成物
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
SK180499A3 (en) * 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
YU68299A (sh) * 1997-07-01 2002-06-19 Pfizer Products Inc. Preparati rastvorenog sertralina
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EA003990B1 (ru) * 1998-10-13 2003-12-25 Пфайзер Продактс Инк. Пероральный концентрат сертралина
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
PL377479A1 (pl) * 2002-12-11 2006-02-06 Pfizer Products Inc. Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210078244A1 (en) * 2018-01-09 2021-03-18 Triastek Inc. Dosage forms with desired release profiles and methods of designing and making thereof

Also Published As

Publication number Publication date
PE20020307A1 (es) 2002-04-23
AU2002229141A1 (en) 2002-02-18
OA12365A (en) 2006-05-16
AP2001002237A0 (en) 2001-09-30
CN1461212A (zh) 2003-12-10
IS6686A (is) 2003-01-16
ECSP034455A (es) 2003-03-10
UY26876A1 (es) 2002-03-22
IL154012A0 (en) 2003-07-31
SV2002000586A (es) 2002-10-24
CA2418907A1 (en) 2002-02-14
HUP0300722A2 (hu) 2003-11-28
EA200300081A1 (ru) 2003-08-28
BG107538A (bg) 2003-11-28
TNSN01123A1 (fr) 2005-11-10
BR0113067A (pt) 2003-07-01
GT200100161A (es) 2002-03-22
US20030086972A1 (en) 2003-05-08
WO2002011702A3 (en) 2002-11-28
WO2002011702A2 (en) 2002-02-14
MXPA03001209A (es) 2003-06-30
US20040052845A1 (en) 2004-03-18
PL360658A1 (en) 2004-09-20
EP1326587A2 (en) 2003-07-16
NO20030627L (no) 2003-04-08
PA8524901A1 (es) 2002-04-25
KR20030024844A (ko) 2003-03-26
MA26939A1 (fr) 2004-12-20
JP2004505907A (ja) 2004-02-26
HRP20030082A2 (en) 2003-04-30
DOP2001000229A (es) 2002-09-30
NO20030627D0 (no) 2003-02-07

Similar Documents

Publication Publication Date Title
EE200300055A (et) Hüdrogeeli poolt juhitav ravimi annustamisvorm
NO20022970D0 (no) Hydrogel-drevet medikamentdoseringsform
ATE311915T1 (de) Medikamentenspender
EP1477403A4 (en) MEDICINES SUPPLY
DE60016271D1 (de) Medikamentenzuführvorrichtung
DE60014279D1 (de) Stiftförmige Medikamentenspritze
NO2013004I1 (no) axitinib, valgfritt i form av et farmasøytisk aksentabelt salt
ATE411068T1 (de) Medikamentspender
DE50002776D1 (de) Fungizide wirkstoffkombinationen
NO20004196D0 (no) Innretninger for legemiddelavlevering
EE200300416A (et) Ravimvorm
DE50102752D1 (de) Fungizide wirkstoffkombinationen
DE50007895D1 (de) Fungizide wirkstoffkombinationen
PT1200444E (pt) Novos compostos xantona, sua preparacao e sua utilizacao como medicamento
FR2820311B3 (fr) Distributeur de medicament portatif
IS6163A (is) Lyfjakomplex
DE50002125D1 (de) Fungizide wirkstoffkombinationen
ATA8202001A (de) Medikamentenapplikator
EE200300378A (et) Farmatseutiline kompositsioon
SE0004677D0 (sv) Intraaxonal läkemedelsadministration
DE50008261D1 (de) Retardierte darreichungsform enthaltend tramadolsaccharinat
DK1221917T3 (da) Anordning til lægemiddelafgivelse
SE0102823D0 (sv) New drug
SE0101543D0 (sv) A drug for increased oxygenation
IL134581A0 (en) Pharmaceutical dosage form